KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $0.315 $0.440 Friday, 26th Apr 2024 GLMD stock ended at $0.392. This is 0.229% less than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 5.87% from a day low at $0.373 to a day high of $0.395.
90 days $0.300 $0.466
52 weeks $0.260 $5.63

Historical Galmed Pharmaceuticals Ltd. prices

Date Open High Low Close Volume
Mar 21, 2024 $0.305 $0.318 $0.305 $0.316 53 970
Mar 20, 2024 $0.315 $0.320 $0.300 $0.305 78 246
Mar 19, 2024 $0.320 $0.329 $0.303 $0.313 80 083
Mar 18, 2024 $0.300 $0.350 $0.300 $0.311 295 239
Mar 15, 2024 $0.410 $0.410 $0.301 $0.305 3 450 208
Mar 14, 2024 $0.360 $0.360 $0.320 $0.349 34 062
Mar 13, 2024 $0.370 $0.370 $0.350 $0.360 20 165
Mar 12, 2024 $0.390 $0.390 $0.360 $0.360 34 803
Mar 11, 2024 $0.380 $0.380 $0.368 $0.370 37 692
Mar 08, 2024 $0.389 $0.395 $0.370 $0.380 11 800
Mar 07, 2024 $0.388 $0.390 $0.367 $0.380 23 856
Mar 06, 2024 $0.363 $0.381 $0.363 $0.370 47 000
Mar 05, 2024 $0.398 $0.398 $0.350 $0.385 125 736
Mar 04, 2024 $0.405 $0.429 $0.390 $0.391 87 072
Mar 01, 2024 $0.419 $0.420 $0.390 $0.410 195 750
Feb 29, 2024 $0.412 $0.412 $0.392 $0.396 103 891
Feb 28, 2024 $0.389 $0.410 $0.375 $0.400 160 898
Feb 27, 2024 $0.370 $0.389 $0.367 $0.384 162 731
Feb 26, 2024 $0.360 $0.390 $0.360 $0.368 44 423
Feb 23, 2024 $0.360 $0.365 $0.360 $0.363 31 362
Feb 22, 2024 $0.380 $0.395 $0.340 $0.360 100 657
Feb 21, 2024 $0.380 $0.395 $0.361 $0.362 28 018
Feb 20, 2024 $0.400 $0.400 $0.365 $0.380 29 508
Feb 16, 2024 $0.376 $0.395 $0.353 $0.385 37 934
Feb 15, 2024 $0.370 $0.385 $0.355 $0.380 50 156
Click to get the best stock tips daily for free!

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinica... GLMD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT